SCHEMBL2287208

SCHEMBL2287208

CCOC(=O)C1(C)CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 1/20 0.38
FFAR3 O14843 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
OPRM1 P35372 3/20 0.37
P2RX7 Q99572 1/20 0.37
KDM4E B2RXH2 3/20 0.36
ATM Q13315 1/20 0.36
OPRD1 P41143 2/20 0.36
OPRK1 P41145 2/20 0.36
ALOX15 P16050 1/20 0.36
SLC22A1 O15245 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16541489 1.00 BRD4 (0.41) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL60903 0.98 BRD4 (0.41) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL265557 0.93 SMN1; SMN2 (0.45) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2289941 0.91
SCHEMBL21328019 0.85 ALDH1A1 (0.39) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL16471455 0.84 BRD4 (0.40) BRD4SMN1; SMN2MEN1KMT2APOLB
SCHEMBL1439277 0.83 CYP3A4 (0.40) SMN1; SMN2ALDH1A1MEN1KMT2APOLB
SCHEMBL16841440 0.83 BRD4 (0.41) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL16751006 0.83 BRD4 (0.41) BRD4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL29642954 0.83 FFAR3 (0.37) SMN1; SMN2ALDH1A1MEN1KMT2AFFAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112041316-B Isoxazole O-linked carbamoyl cyclohexyl acids as LPA antagonists 百时美施贵宝公司 2024-11-22 CN disclosed
US-20230221640-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2023-07-13 US disclosed
EP-4124616-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS Alkermes Pharma Ireland Limited (IE) 2023-02-01 EP disclosed
EP-2445502-B2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS ALKERMES PHARMA IRELAND LTD (IE) 2022-09-28 EP disclosed
US-11256173-B2 Treatment liquid for manufacturing semiconductor and pattern forming method FUJIFILM CORPORATION (JP) 2022-02-22 US disclosed
US-20210103217-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, AND PHOTO MASK FUJIFILM CORPORATION (JP) 2021-04-08 US disclosed
WO-2019179928-A1 SUBSTITUTED SUCCINIMIDE-3-CARBOXAMIDES, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2019-09-26 WO disclosed
US-20190025702-A1 TREATMENT LIQUID FOR MANUFACTURING SEMICONDUCTOR AND PATTERN FORMING METHOD FUJIFILM CORPORATION (JP) 2019-01-24 US disclosed
US-10040787-B2 Prodrugs of NH-acidic compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2018-08-07 US disclosed
US-10011569-B2 Process for synthesizing oxidized lactam compounds ALKERMES PHARMA IRELAND LIMITED (IE) 2018-07-03 US disclosed
US-4347160-A Titanium halide catalyst system STAUFFER CHEMICAL COMPANY (US) 1982-08-31 US disclosed
US-4325836-A Novel titanium halide containing catalyst STAUFFER CHEMICAL COMPANY (US) 1982-04-20 US disclosed
EP-0044445-A2 Titanium halide containing catalyst STAUFFER CHEMICAL COMPANY (US) 1982-01-27 EP disclosed
US-4312782-A COORDINATION CATALYST FOR POLYMERIZATION OF ALPHA OLEFINS STAUFFER CHEMICAL COMPANY (US) 1982-01-26 US disclosed
EP-0043185-A1 Method for production of titanium halide catalyst component, catalyst system including such component, and polymerization of alpha-olefins using such system STAUFFER CHEMICAL COMPANY (US) 1982-01-06 EP disclosed
EP-0040711-A1 Titanium halide catalyst for polymerization STAUFFER CHEMICAL COMPANY (US) 1981-12-02 EP disclosed
US-4294948-A Process for preparing olefin polymers or copolymers, and catalyst for use in said process MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) 1981-10-13 US disclosed
US-4232139-A Process for producing polymers or copolymers of olefins containing at least 3 carbon atoms MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) 1980-11-04 US disclosed
US-4221894-A MAGNESIUM HALIDE, TITANIUM, ORGANOALUMINUM, ESTER MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) 1980-09-09 US disclosed
US-4143223-A TITANIUM, HALOGEN, ALUMINUM, ESTER AND AN ALCOHOL MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) 1979-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011569-B2 Process for synthesizing oxidized lactam compounds COASY, DHPS, OXA1L BRD4 2924/4885SMN1; SMN2 3665/4885ALDH1A1 113/4885
US-10040787-B2 Prodrugs of NH-acidic compounds SI, NAAA, NIT2 BRD4 2833/4885SMN1; SMN2 606/4885ALDH1A1 1082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.